SCHEMBL7153204

SCHEMBL7153204

Cc1cccc(NS(=O)(=O)CCCCSc2nc3cc4c(cc3s2)OCO4)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 12/20 0.41
LMNA P02545 4/20 0.41
THRB P10828 1/20 0.40
POLB P06746 4/20 0.39
TP53 P04637 2/20 0.39
BLM P54132 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTT P42858 2/20 0.37
PKM P14618 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151043 0.97 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7151763 0.94 POLB (0.42) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7149221 0.90 LMNA (0.47) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7147149 0.89 MAPT (0.43) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7154989 0.87 LMNA (0.48) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7153034 0.86 MAPT (0.44) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7148116 0.86 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7151259 0.85 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MAPTLMNATHRB
SCHEMBL7149819 0.84 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPTLMNAPOLB
SCHEMBL7149163 0.84 MAPT (0.46) ALDH1A1SMN1; SMN2MAPTLMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885SMN1; SMN2 3295/4885MAPT 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.